HMG-COA REDUCTASE INHIBITORS IN THE PREVENTION OF RESTENOSIS FOLLOWING CORONARY ANGLOPLASTY

摘要

1029s/5516P 18435 TITLE OF THE INVENTION HMG-CoA REDUCTASE INHIBITORS IN THE PREVENTION OF RESTENOSIS FOLLOWING CORONARY ANGIOPLASTY Treatment of coronary patients scheduled to undergo percutaneous transluminal coronary angioplasty (PTCA) for several days before the procedure and a prolonged period afterwards with doses of a HMG-CoA reductase inhibitor to aggressively lower total and LDL cholesterol prevents intimal hyperplasia at the angioplasty site reducing clinical and angiographic evidence of restenosis.